IL1RAP and chronic myelogenous leukemia, BCR-ABL1 positive: Similarly, in this study, we identified IL1RAP upregulation on CML LSCs; the availability of IL-1 receptor antagonists or decoy receptors that are currently FDA-approved for the treatment of several inflammatory disorders[36] may allow effective targeting of the CML LSC.